Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05239143 · ClinicalTrials.gov registry record · Phase 1
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
A Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by Poseida Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 180
- Enrollment target
- 14
- Study locations
NCT05239143 is a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Poseida Therapeutics. The registered enrollment target is 180 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The trial reports 14 study locations across 9 states.
The verdict
NCT05239143, a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Poseida Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 180 participants
- Enrollment target
- 14
- Study locations
Study Summary
A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.
Conditions Studied
Interventions
- DRUG Rimiducid
- BIOLOGICAL P-MUC1C-ALLO1 CAR-T cells
Study Locations (14)
California
- University of California, Irvine Medical Center - Irvine
- Cedars Sinai Medical Center - Los Angeles
- University of California, San Diego - San Diego
- University of California, San Francisco - San Francisco
Kansas
- University of Kansas Cancer Center - Westwood
- Cancer Center of Kansas - Wichita
Texas
- MD Anderson Cancer Center - Houston
- NEXT Oncology - San Antonio
Colorado
- Sarah Cannon Research Institute at HealthONE - Denver
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Maryland
- University of Maryland Cancer Center - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Nebraska
- University of Nebraska Medical Center - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2022-02-15 |
| Est. Completion | 2039-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05239143
The ClinicalTrials.gov registry entry for NCT05239143 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Poseida Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Rimiducid is the first listed.
NCT05239143 reports 14 study locations spanning 9 distinct geographic areas - top geographies include California, Kansas, Texas.
Frequently Asked Questions
What is clinical trial NCT05239143 about?
NCT05239143 is a clinical study titled "P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors". A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.
What is the current status of trial NCT05239143?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2022-02-15. Estimated completion is 2039-04.
What conditions does trial NCT05239143 study?
This clinical trial studies the following conditions: Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer.
What interventions are being tested in trial NCT05239143?
The interventions under investigation include: Rimiducid (DRUG), P-MUC1C-ALLO1 CAR-T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT05239143?
This trial is sponsored by Poseida Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05239143 being conducted?
This trial has 14 study locations across California, Colorado, Iowa, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.